Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations

被引：0

作者：

Garmezy, B. ^{[1
]}

Borad, M. ^{[2
]}

Lin, C. C. ^{[3
]}

Chen, L. T. ^{[4
]}

Perez, C. A. ^{[5
]}

Kato, S. ^{[6
]}

Tam, B. ^{[7
]}

Severson, P. ^{[8
]}

Quah, C. S. ^{[9
]}

Harding, J. J. ^{[10
]}

机构：

[1] Sarah Cannon Res Inst, Res, Nashville, TN USA

[2] Mayo Clin, Ctr Canc, Oncol Dept, Scottsdale, AZ USA

[3] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[4] Kaohsiung Med Univ, Chung Ho Mem Hosp, Hematol Dept, Kaohsiung, Taiwan

[5] Florida Canc Specialists, Med Oncol, Ft Myers, FL USA

[6] Univ Calif San Diego UCSD, Med Oncol, La Jolla, CA USA

[7] Kinnate Biopharma, Clin Sci, San Diego, CA USA

[8] Kinnate Biopharma Inc, Translat Med, San Diego, CA USA

[9] Kinnate Biopharma, Clin Dev, San Diego, CA USA

[10] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Med, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1423

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

130P

引用

页码：S231 / S232

页数：2

共 46 条

[41] Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
Javle, Milind M.
Borbath, Ivan
Clarke, Stephen John
Hitre, Erika
Louvet, Christophe
Mercade, Teresa Macarulla
Oh, Do-Youn
Spratlin, Jennifer L.
Valle, Juan W.
Weiss, Karl Heinz
Berman, Craig
Howland, Michael
Ye, Yining
Cho, Terry
Moran, Susan
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[42] FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations
Feliz, Luis
Asatiani, Ekaterine
Lihou, Christine
Zhen, Huiling
Silverman, Ian
Ahnert, Jordi Rodon
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[43] A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors
ODonnell, P.
Goldman, J. W.
Gordon, M. S.
Shih, K.
Choi, Y. J.
Lu, D.
Kabbarah, O.
Ho, W.
Rooney, I.
Lam, E. T.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 191 - 192
[44] Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Javle, M.
Borbath, I.
Clarke, S.
Hitre, E.
Louver, C.
Macarulla, T.
Oh, D.
Spratlin, J.
Valee, J.
Weiss, K.
Berman, C.
Howland, M.
Ye, Y.
Cho, T.
Moran, S.
Abou-Alfa, C.
ANNALS OF ONCOLOGY, 2019, 30 : 62 - 62
[45] A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3)
Borad, Mitesh J.
Bridgewater, John A.
Morizane, Chigusa
Shroff, Rachna T.
Oh, Do-Youn
Moehler, Markus H.
Furuse, Junji
Benhadji, Karim A.
He, Helen
Valle, Juan W.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[46] Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations
Moreno, Victor
Loriot, Yohann
Valderrama, Begona Perez
Beato, Carmen
Vano, Yann-Alexandre
Fleming, Mark T.
Duran, Ignacio
Siena, Salvatore
Tolbert, Jaszianne A.
OHagan, Anne
Akapame, Sydney
Lau, Yvonne Y.
Geoffrois, Lionnel
Tagawa, Scott T.
Mellado, Begona
Siefker-Radtke, Arlene O.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)

← 1 2 3 4 5 →